Library

Sibutramine

Sibutramine was withdrawn from most markets in 2010 due to increased risk of cardiovascular events (heart attack and stroke), particularly in patients with pre-existing cardiovascular disease. It is a centrally acting appetite suppressant that acts as a prodrug, metabolized to more potent active metabolites (M1 and M2) with longer half-lives. Unlike amphetamines, it does not cause monoamine release and does not produce euphoria. Contraindicated in patients with history of cardiovascular disease, uncontrolled hypertension, eating disorders, severe depression, mania, or narrow-angle glaucoma. Regular blood pressure monitoring is essential during use.

Sibutramine molecular structure
Sibutramine molecular structure diagram from the DrugsPRO substance library.

Also known as: Meridia, Siredia, Reductil, Sibutrex, Butramin, Medaria, (±)-Dimethyl-1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine

Classification

  • Chemical: Medicine
  • Psychoactive: Stimulant
  • Tag: Appetite-suppressant
  • Tag: Pharmaceutical
  • Tag: Withdrawn-medication

Effects

  • Stimulation
  • Increased Energy
  • Increased Heart Rate
  • Increased Blood Pressure
  • Dry Mouth
  • Insomnia
  • Anxiety
  • Dizziness
  • Talkativeness
  • Alertness Enhancement
  • Wakefulness
  • Focus Enhancement
  • Appetite Suppression
  • Light Sensitivity
  • Dehydration
  • Photophobia
  • Spontaneous Physical Sensations
  • Increased Libido

Routes of Administration

Oral

Dosage

  • Threshold: 5 mg
  • Light: 5-10 mg
  • Common: 10-15 mg
  • Strong: 15-20 mg
  • Heavy: 20+ mg

Duration

  • Onset: 0.5-2 h
  • Comeup: 1-2 h
  • Peak: 3-6 h
  • Offset: 12-24 h
  • After Effects: 18-36 h
  • Total Duration: 18-30 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu

Sibutramine - DrugsPRO stofgids

Sibutramine: Sibutramine was withdrawn from most markets in 2010 due to increased risk of cardiovascular events (heart attack and stroke), particularly in patients with pre-existing cardiovascular disease. It is a centrally acting appetite suppressant that acts as a prodrug, metabolized to more pote

Related pages